Phase 3 Clinical Trials With Primary Completion Dates in May 2016
This is a list of Phase 3 trials with primary completion dates in May 2016 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| ACRX | AcelRx Pharmaceuticals, Inc. | 2016-05-01 | Phase 3 | NCT02662556 | A Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg in Patients With Post-Operative Pain |
| ACRX | AcelRx Pharmaceuticals, Inc. | 2016-05-01 | Phase 3 | NCT02447848 | A Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of the Sublingual Sufentanil Tablet 30 mcg for the Treatment of Acute Pain |
| AERI | Aerie Pharmaceuticals, Inc. | 2016-05-01 | Phase 3 | NCT02246764 | Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension |
| ALKS | Alkermes plc | 2016-05-01 | Phase 3 | NCT01895452 | An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070) |
| CHRS | Coherus BioSciences, Inc. | 2016-05-01 | Phase 3 | NCT02489227 | Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis |
| CLCD | CoLucid Pharmaceuticals, Inc. | 2016-05-01 | Phase 3 | NCT02439320 | Lasmiditan Compared to Placebo in the Acute Treatment of Migraine: |
| CPRX | Catalyst Pharmaceuticals, Inc. | 2016-05-01 | Phase 3 | NCT02562066 | Amifampridine Phosphate for the Treatment of Pediatric Congenital Myasthenic Syndromes |
| DPRX | Dipexium Pharmaceuticals, Inc. | 2016-05-01 | Phase 3 | NCT01594762 | Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers |
| DPRX | Dipexium Pharmaceuticals, Inc. | 2016-05-01 | Phase 3 | NCT01590758 | Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers |
| INNL | Innocoll Holdings | 2016-05-01 | Phase 3 | NCT02447172 | Study of a Topical Gentamicin-Collagen Sponge Along With Systemic Antibiotic in Infected Diabetic Foot Ulcers |
| INNL | Innocoll Holdings | 2016-05-01 | Phase 3 | NCT02427802 | Study of a Topical Gentamicin-Collagen Sponge Along With Systemic Antibiotic in Infected Diabetic Foot Ulcers |
| ITCI | Intra-Cellular Therapies Inc. | 2016-05-01 | Phase 3 | NCT02469155 | A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment |
| JAZZ | Jazz Pharmaceuticals plc | 2016-05-01 | Phase 3 | NCT02348619 | "Six-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA" |
| LCI | Lannett Co Inc | 2016-05-01 | Phase 3 | NCT02500836 | Topical Application of Cocaine HCl 4%, or 10%, or Placebo Solution in Local (Topical) Anesthesia |
| MCUR | MACROCURE LTD. | 2016-05-01 | Phase 3 | NCT02130310 | Evaluation of CureXcell® in Treating Chronic Venous Leg Ulcers |
| MMSI | Merit Medical Systems, Inc. | 2016-05-01 | Phase 3 | NCT01789840 | Prostate Artery Embolization With Embosphere Microspheres Compared to TURP for Benign Prostatic Hyperplasia |
| OCUL | Ocular Therapeutix, Inc. | 2016-05-01 | Phase 3 | NCT02445326 | Study Evaluating Efficacy and Safety of OTX-DP for Treatment of Chronic Allergic Conjunctivitis |
| RARE | Ultragenyx Pharmaceutical Inc. | 2016-05-01 | Phase 3 | NCT02230566 | A Phase 3 Study of UX003 rhGUS Enzyme Replacement Therapy in Patients With MPS 7 |
| SGEN | Seattle Genetics, Inc. | 2016-05-01 | Phase 3 | NCT01578499 | A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma |
| XENT | Intersect ENT, Inc. | 2016-05-01 | Phase 3 | NCT02266810 | Safety and Efficacy of the Propel Mini and Propel Nova Steroid-Eluting Sinus Implant in Frontal Sinus |